Idelalisib: a rare cause of enterocolitis

被引：10

作者：

Balagoni, Harika ^{[1
,2
]}

Chaudhari, Dhara ^{[1
,3
]}

Reddy, Chakradhar ^{[1
,3
]}

Young, Mark ^{[1
,3
]}

机构：

[1] E Tennessee State Univ, James H Quillen Coll Med, Johnson City, TN 37614 USA

[2] E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Johnson City, TN 37614 USA

[3] E Tennessee State Univ, James H Quillen Coll Med, Dept Gastroenterol, Johnson City, TN 37614 USA

来源：

ANNALS OF GASTROENTEROLOGY | 2016年 / 29卷 / 02期

关键词：

Idelalisib; enterocolitis; diarrhea;

D O I：

10.20524/aog.2016.0022

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma. Data from three phases of the study involving idelalisib demonstrate diarrhea (47%) to be the common adverse effect. The other side effects are pyrexia (28%), fatigue (30%), nausea (29%), cough (29%), pneumonia (25%), abdominal pain (26%) and rash (21%). The characteristic histological findings of idelalisib colitis include intraepithelial lymphocytosis, neutrophilic cryptitis and epithelial cell apoptosis within the crypts. Histological findings help differentiate among other causes of diarrhea and entero-colitis. We present a female patient with recurrent follicular lymphoma treated with idelalisib and presented with diarrhea. She was found to have entero-colitis and was treated successfully with drug discontinuation and prednisone.

引用

页码：233 / 235

页数：3

共 9 条

[1]

[Anonymous], LEUK LYMPHOMA

[2] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia [J].

Furman, Richard R. ;

Sharman, Jeff P. ;

Coutre, Steven E. ;

Cheson, Bruce D. ;

Pagel, John M. ;

Hillmen, Peter ;

Barrientos, Jacqueline C. ;

Zelenetz, Andrew D. ;

Kipps, Thomas J. ;

Flinn, Ian ;

Ghia, Paolo ;

Eradat, Herbert ;

Ervin, Thomas ;

Lamanna, Nicole ;

Coiffier, Bertrand ;

Pettitt, Andrew R. ;

Ma, Shuo ;

Stilgenbauer, Stephan ;

Cramer, Paula ;

Aiello, Maria ;

Johnson, Dave M. ;

Miller, Langdon L. ;

Li, Daniel ;

Jahn, Thomas M. ;

Dansey, Roger D. ;

Hallek, Michael ;

O'Brien, Susan M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :997-1007

[3]

Lamps L., 2015, SURG PATHOLOGY GI TR

[4] CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability [J].

Lannutti, Brian J. ;

Meadows, Sarah A. ;

Herman, Sarah E. M. ;

Kashishian, Adam ;

Steiner, Bart ;

Johnson, Amy J. ;

Byrd, John C. ;

Tyner, Jeffrey W. ;

Loriaux, Marc M. ;

Deininger, Mike ;

Druker, Brian J. ;

Puri, Kamal D. ;

Ulrich, Roger G. ;

Giese, Neill A. .

BLOOD, 2011, 117 (02) :591-594

[5] Idelalisib-associated Enterocolitis Clinicopathologic Features and Distinction From Other Enterocolitides [J].

Louie, Christine Y. ;

DiMaio, Michael A. ;

Matsukuma, Karen E. ;

Coutre, Steven E. ;

Berry, Gerald J. ;

Longacre, Teri A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (12) :1653-1660

[6]

U.S. Food and Drug Administration, ID DRUG INF

[7]

US Department of Health and Human Services National Institutes of Health National Cancer Institute, 2009, COMMON TERMINOLOGY C

[8] Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets [J].

Wei, B ;

Velazquez, P ;

Turovskaya, O ;

Spricher, K ;

Aranda, R ;

Kronenberg, M ;

Birnbaumer, L ;

Braun, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (06) :2010-2015

[9] Idelalisib-associated Colitis Histologic Findings in 14 Patients [J].

Weidner, Anna-Sophie ;

Panarelli, Nicole C. ;

Geyer, Julia T. ;

Bhavsar, Erica B. ;

Furman, Richard R. ;

Leonard, John P. ;

Jessurun, Jose ;

Yantiss, Rhonda K. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (12) :1661-1667

← 1 →